Results 81 to 90 of about 5,389 (186)

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma [PDF]

Background: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma ...
Arance, Ana, Ascierto, Paolo A, de Groot, Jan Willem B, di Pietro, Alessandra, Dummer, Reinhard, Flaherty, Keith T, Garbe, Claus, Gogas, Helen J, Guenzel, Carolin, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Polli, Anna, Queirolo, Paola, Robert, Caroline, Schadendorf, Dirk, Thakur, Mahgull, Yamazaki, Naoya   +19 more
core   +1 more source

Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Purpose A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assessing the effect of systemic therapy compared to surveillance are limited, and factors associated with ...
Derek Effiom, Tyler Aprati, Anastasios Karneris, Aleigha Lawless, Tatyana Sharova, Rebecca Johnson, Alexander Menzies, Georgina Long, Benjamin Park, Seungyeon Jung, Douglas Johnson, David Liu, Xue Bai, Keith Flaherty, Ryan Sullivan, Genevieve M. Boland, Sonia Cohen   +16 more
wiley   +1 more source

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study [PDF]

Mutació; Càncer colorectal; Teràpia dirigidaMutation; Colorectal cancer; Targeted therapyMutación; Cáncer colorrectal; Terapia dirigidaBackground The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E ...
Auclin, Edouard, Bergen, Elisabeth, Gallois, Claire, Higué, J., Pernot, Simon, Ros, Javier, Trouilloud, I.   +6 more
core   +1 more source

Real‐World Molecular Testing in European Early‐Onset Colorectal Cancer

United European Gastroenterology Journal, Volume 13, Issue 10, Page 2012-2022, December 2025.
ABSTRACT Purpose The global incidence and mortality of early‐age onset colorectal cancer (EOCRC, or CRC diagnosed under 50 years) has increased in recent decades. High‐risk surveillance and personalised oncological treatment may improve patients' outcomes.
Penelope V. Edwards, Kussai Giuma Ali Eloussta, Andrew Latchford, Omar Faiz, Huw Thomas, Filomena Liccardo, Nikhil Pawa, Robert Hüneburg, Jacob Nattermann, Andrew George, Francesc Balaguer, Marc Martí, Antonino Spinelli, Caterina Foppa, Noel F. F. C. de Miranda, Irene López, Elena Hurtado, Fernando Jiménez, Marta Jiménez‐Toscano, Edurne Álvaro, Gonzalo Sanz, Araceli Ballestero, José A. Rueda, Cristina Viyuela, Lorena Brandáriz, Rosario Vidal‐Tocino, Damián García‐Olmo, Carlos Pastor, Rogelio González‐Sarmiento, Andreana N. Holowatyj, Terri McVeigh, José Perea, Kevin J. Monahan, On behalf of Collaborators GEOCODE and SECOC Consortia   +33 more
wiley   +1 more source

B-Raf-Mutated Melanoma [PDF]

, 2020
Until fairly recently, treatment options for advanced melanoma have been relatively limited. Fortunately, the last decade has seen dramatic improvements in response rates and duration of overall survival after the introduction of checkpoint inhibitors ...
Chandra, Sunandana, Fenton, Sarah E., Sosman, Jeffrey A.   +2 more
core   +1 more source

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma

Pigment Cell &Melanoma Research, Volume 38, Issue 6, November 2025.
(A) NRAS mutations in melanoma lock the NRAS protein in its active state, driving constitutive activation of the MAPK pathway and promoting cell proliferation. Activation of RAF proteins by RAS mutations involves not only BRAF but also CRAF. (B) Inhibition of the downstream kinase MEK by mirdametinib reduces signaling to the ERK kinase but also ...
Flavia L. Tellenbach, Luzia Seiler, Mark Johnson, Hubert Rehrauer, Prachi Schukla, Julia Martinez‐Gomez, Corinne I. Stoffel, Adeela Kamal, Reinhard Dummer, Mitchell P. Levesque, Ossia M. Eichhoff   +10 more
wiley   +1 more source

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. [PDF]

BACKGROUND: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with BRAF V600-mutant melanoma with asymptomatic brain metastases.
Ascierto, Paolo, Davies, Michael, di Pietro, Alessandra, Fein, Luis, Flaherty, Keith, Guenzel, Carolin, Hamid, Omid, Kleha, Joseph, Kohn, Amiee, Lewis, Karl, Long, Georgina, McArthur, Grant, Menzies, Alexander, Pfluger, Yanina, Prenen, Hans, Tawbi, Hussein, Tsai, Katy, Wang, Erjian, Weber, Jeffrey, Zhang, Fan   +19 more
core   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review

Case Reports in Oncology
Introduction: Encorafenib and binimetinib, a combination of BRAF and MEK inhibitors, is a standard of care for patients with advanced BRAFV600-mutant melanoma.
Chloe Wautier, Jolanta Gourmaud, Catherine Dong, Gregoire Berthod   +3 more
doaj   +1 more source

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma [PDF]

Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable BRAFV600-mutant melanoma is unknown. The SECOMBIT trial examined the impact
Arance, Ana, Ascierto, Paolo A., Bulgarelli, Jenny, Casula, Milena, Cossu, Antonio, De Placido, Sabino, Del Vecchio, Michele, Dummer, Reinhard, Ferraresi, Virginia, Ferrucci, Pier Francesco, Giannarelli, Diana, Gogas, Helen, Gonzalez-Cao, Maria, Grimaldi, Antonio M., Guida, Michele, Guidoboni, Massimo, Helgadottir, Hildur, Lebbé, Céleste, Maiello, Evaristo, Mallardo, Domenico, Mandalà, Mario, Melero, Ignacio, Minisini, Alessandro Marco, Palmieri, Giuseppe, Paone, Miriam, Piccin, Luisa, Piccinini, Claudia, Pisano, Marina, Quaglino, Pietro, Queirolo, Paola, Richtig, Erika, Rutkowski, Piotr, Sanmamed, Miguel F., Sileni, Vanna Chiarion, Spagnolo, Francesco, Tucci, Marco, Vitale, Maria Grazia   +36 more
core   +1 more source